nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—salivary gland cancer	0.821	1	CtDrD
Sorafenib—CDK7—connective tissue—salivary gland cancer	0.00124	0.024	CbGeAlD
Sorafenib—HIPK3—connective tissue—salivary gland cancer	0.00105	0.0203	CbGeAlD
Sorafenib—EPHX2—parotid gland—salivary gland cancer	0.00102	0.0198	CbGeAlD
Sorafenib—RET—neck—salivary gland cancer	0.001	0.0193	CbGeAlD
Sorafenib—TIE1—epithelium—salivary gland cancer	0.000934	0.018	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—salivary gland cancer	0.00091	0.0176	CbGeAlD
Sorafenib—FLT3—connective tissue—salivary gland cancer	0.000895	0.0173	CbGeAlD
Sorafenib—FLT1—neck—salivary gland cancer	0.000882	0.017	CbGeAlD
Sorafenib—RAF1—neck—salivary gland cancer	0.000877	0.0169	CbGeAlD
Sorafenib—MAP3K7—parotid gland—salivary gland cancer	0.000863	0.0167	CbGeAlD
Sorafenib—MKNK2—parotid gland—salivary gland cancer	0.000836	0.0162	CbGeAlD
Sorafenib—MAP3K7—saliva-secreting gland—salivary gland cancer	0.000826	0.016	CbGeAlD
Sorafenib—MKNK2—saliva-secreting gland—salivary gland cancer	0.000801	0.0155	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—salivary gland cancer	0.000786	0.0152	CbGeAlD
Sorafenib—FLT4—epithelium—salivary gland cancer	0.000772	0.0149	CbGeAlD
Sorafenib—RALBP1—parotid gland—salivary gland cancer	0.000755	0.0146	CbGeAlD
Sorafenib—KDR—neck—salivary gland cancer	0.000745	0.0144	CbGeAlD
Sorafenib—MKNK2—connective tissue—salivary gland cancer	0.000736	0.0142	CbGeAlD
Sorafenib—RALBP1—saliva-secreting gland—salivary gland cancer	0.000723	0.014	CbGeAlD
Sorafenib—FLT1—parotid gland—salivary gland cancer	0.000718	0.0139	CbGeAlD
Sorafenib—RET—connective tissue—salivary gland cancer	0.000718	0.0139	CbGeAlD
Sorafenib—RAF1—parotid gland—salivary gland cancer	0.000714	0.0138	CbGeAlD
Sorafenib—EPHB6—parotid gland—salivary gland cancer	0.00071	0.0137	CbGeAlD
Sorafenib—MKNK2—epithelium—salivary gland cancer	0.000699	0.0135	CbGeAlD
Sorafenib—FLT1—saliva-secreting gland—salivary gland cancer	0.000688	0.0133	CbGeAlD
Sorafenib—RAF1—saliva-secreting gland—salivary gland cancer	0.000684	0.0132	CbGeAlD
Sorafenib—RET—epithelium—salivary gland cancer	0.000681	0.0132	CbGeAlD
Sorafenib—EPHB6—saliva-secreting gland—salivary gland cancer	0.00068	0.0131	CbGeAlD
Sorafenib—KIT—neck—salivary gland cancer	0.000661	0.0128	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—salivary gland cancer	0.000654	0.0126	CbGeAlD
Sorafenib—PDGFRB—neck—salivary gland cancer	0.000645	0.0125	CbGeAlD
Sorafenib—FLT1—connective tissue—salivary gland cancer	0.000632	0.0122	CbGeAlD
Sorafenib—RAF1—connective tissue—salivary gland cancer	0.000628	0.0121	CbGeAlD
Sorafenib—MAP2K5—parotid gland—salivary gland cancer	0.000607	0.0117	CbGeAlD
Sorafenib—KDR—parotid gland—salivary gland cancer	0.000607	0.0117	CbGeAlD
Sorafenib—FLT1—epithelium—salivary gland cancer	0.0006	0.0116	CbGeAlD
Sorafenib—RAF1—epithelium—salivary gland cancer	0.000597	0.0115	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—salivary gland cancer	0.000594	0.0115	CbGeAlD
Sorafenib—PDGFRA—connective tissue—salivary gland cancer	0.000592	0.0114	CbGeAlD
Sorafenib—MAP2K5—saliva-secreting gland—salivary gland cancer	0.000581	0.0112	CbGeAlD
Sorafenib—KDR—saliva-secreting gland—salivary gland cancer	0.000581	0.0112	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—salivary gland cancer	0.000538	0.0104	CbGeAlD
Sorafenib—KIT—parotid gland—salivary gland cancer	0.000538	0.0104	CbGeAlD
Sorafenib—KDR—connective tissue—salivary gland cancer	0.000534	0.0103	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—salivary gland cancer	0.000531	0.0103	CbGeAlD
Sorafenib—PDGFRB—parotid gland—salivary gland cancer	0.000526	0.0102	CbGeAlD
Sorafenib—RET—lymphoid tissue—salivary gland cancer	0.000525	0.0101	CbGeAlD
Sorafenib—MAPK11—lymph node—salivary gland cancer	0.000522	0.0101	CbGeAlD
Sorafenib—CSF1R—connective tissue—salivary gland cancer	0.000521	0.0101	CbGeAlD
Sorafenib—KIT—saliva-secreting gland—salivary gland cancer	0.000515	0.00996	CbGeAlD
Sorafenib—CDK7—lymph node—salivary gland cancer	0.000513	0.00992	CbGeAlD
Sorafenib—TAOK2—lymph node—salivary gland cancer	0.000509	0.00984	CbGeAlD
Sorafenib—KDR—epithelium—salivary gland cancer	0.000507	0.0098	CbGeAlD
Sorafenib—AURKC—lymph node—salivary gland cancer	0.000505	0.00977	CbGeAlD
Sorafenib—PDGFRB—saliva-secreting gland—salivary gland cancer	0.000503	0.00973	CbGeAlD
Sorafenib—KIT—connective tissue—salivary gland cancer	0.000473	0.00915	CbGeAlD
Sorafenib—PDGFRB—connective tissue—salivary gland cancer	0.000462	0.00894	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—salivary gland cancer	0.000462	0.00893	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—salivary gland cancer	0.000459	0.00888	CbGeAlD
Sorafenib—KIT—epithelium—salivary gland cancer	0.00045	0.00869	CbGeAlD
Sorafenib—ZAK—lymph node—salivary gland cancer	0.000444	0.00857	CbGeAlD
Sorafenib—PDGFRB—epithelium—salivary gland cancer	0.000439	0.00848	CbGeAlD
Sorafenib—STK10—lymphoid tissue—salivary gland cancer	0.000437	0.00845	CbGeAlD
Sorafenib—HIPK3—lymph node—salivary gland cancer	0.000434	0.00839	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—salivary gland cancer	0.000433	0.00837	CbGeAlD
Sorafenib—TIE1—lymph node—salivary gland cancer	0.000406	0.00784	CbGeAlD
Sorafenib—KDR—lymphoid tissue—salivary gland cancer	0.000391	0.00755	CbGeAlD
Sorafenib—BRAF—lymph node—salivary gland cancer	0.000389	0.00752	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—salivary gland cancer	0.000381	0.00737	CbGeAlD
Sorafenib—EPHX2—lymph node—salivary gland cancer	0.000372	0.00719	CbGeAlD
Sorafenib—FLT3—lymph node—salivary gland cancer	0.000369	0.00713	CbGeAlD
Sorafenib—KIT—lymphoid tissue—salivary gland cancer	0.000346	0.00669	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—salivary gland cancer	0.000338	0.00653	CbGeAlD
Sorafenib—FLT4—lymph node—salivary gland cancer	0.000335	0.00648	CbGeAlD
Sorafenib—FGFR1—lymph node—salivary gland cancer	0.000331	0.00639	CbGeAlD
Sorafenib—MAP3K7—lymph node—salivary gland cancer	0.000313	0.00605	CbGeAlD
Sorafenib—MKNK2—lymph node—salivary gland cancer	0.000304	0.00587	CbGeAlD
Sorafenib—MKNK1—lymph node—salivary gland cancer	0.0003	0.00579	CbGeAlD
Sorafenib—RET—lymph node—salivary gland cancer	0.000296	0.00572	CbGeAlD
Sorafenib—ABCG2—parotid gland—salivary gland cancer	0.000295	0.00571	CbGeAlD
Sorafenib—ABCG2—saliva-secreting gland—salivary gland cancer	0.000283	0.00547	CbGeAlD
Sorafenib—RALBP1—lymph node—salivary gland cancer	0.000274	0.0053	CbGeAlD
Sorafenib—FLT1—lymph node—salivary gland cancer	0.000261	0.00504	CbGeAlD
Sorafenib—RAF1—lymph node—salivary gland cancer	0.000259	0.00501	CbGeAlD
Sorafenib—EPHB6—lymph node—salivary gland cancer	0.000258	0.00498	CbGeAlD
Sorafenib—STK10—lymph node—salivary gland cancer	0.000247	0.00477	CbGeAlD
Sorafenib—PDGFRA—lymph node—salivary gland cancer	0.000244	0.00472	CbGeAlD
Sorafenib—KDR—lymph node—salivary gland cancer	0.00022	0.00426	CbGeAlD
Sorafenib—MAP2K5—lymph node—salivary gland cancer	0.00022	0.00426	CbGeAlD
Sorafenib—CSF1R—lymph node—salivary gland cancer	0.000215	0.00416	CbGeAlD
Sorafenib—KIT—lymph node—salivary gland cancer	0.000195	0.00377	CbGeAlD
Sorafenib—PDGFRB—lymph node—salivary gland cancer	0.000191	0.00369	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—salivary gland cancer	0.000175	0.00339	CbGeAlD
Sorafenib—ABCC4—lymph node—salivary gland cancer	0.000152	0.00294	CbGeAlD
Sorafenib—HTR2B—lymph node—salivary gland cancer	0.000151	0.00292	CbGeAlD
Sorafenib—ABCC2—lymph node—salivary gland cancer	0.000147	0.00284	CbGeAlD
Sorafenib—ABCB1—epithelium—salivary gland cancer	0.000122	0.00235	CbGeAlD
Sorafenib—ABCG2—lymph node—salivary gland cancer	0.000107	0.00207	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—salivary gland cancer	9.37e-05	0.00181	CbGeAlD
Sorafenib—ABCB1—lymph node—salivary gland cancer	5.29e-05	0.00102	CbGeAlD
Sorafenib—KIT—Immune System—PTEN—salivary gland cancer	3.95e-06	3.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PTEN—salivary gland cancer	3.95e-06	3.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOTCH1—salivary gland cancer	3.94e-06	3.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOTCH1—salivary gland cancer	3.94e-06	3.1e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CREBBP—salivary gland cancer	3.92e-06	3.09e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—VCAN—salivary gland cancer	3.92e-06	3.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—PIK3CA—salivary gland cancer	3.91e-06	3.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAP2K2—salivary gland cancer	3.91e-06	3.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—salivary gland cancer	3.9e-06	3.07e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—PIK3CA—salivary gland cancer	3.9e-06	3.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CREBBP—salivary gland cancer	3.88e-06	3.05e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—PIK3CA—salivary gland cancer	3.87e-06	3.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FOXO3—salivary gland cancer	3.86e-06	3.04e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—EP300—salivary gland cancer	3.82e-06	3e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—HRAS—salivary gland cancer	3.8e-06	3e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	3.78e-06	2.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HRAS—salivary gland cancer	3.77e-06	2.97e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—EP300—salivary gland cancer	3.76e-06	2.96e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—EP300—salivary gland cancer	3.76e-06	2.96e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—salivary gland cancer	3.75e-06	2.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PTEN—salivary gland cancer	3.74e-06	2.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOTCH1—salivary gland cancer	3.74e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PTEN—salivary gland cancer	3.73e-06	2.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—salivary gland cancer	3.73e-06	2.94e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOTCH1—salivary gland cancer	3.73e-06	2.94e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NUP62—salivary gland cancer	3.72e-06	2.93e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—VCAN—salivary gland cancer	3.69e-06	2.91e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NUP62—salivary gland cancer	3.69e-06	2.9e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—VCAN—salivary gland cancer	3.66e-06	2.88e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAP2K2—salivary gland cancer	3.65e-06	2.88e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTEN—salivary gland cancer	3.64e-06	2.87e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—PIK3CA—salivary gland cancer	3.63e-06	2.86e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—salivary gland cancer	3.62e-06	2.85e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—salivary gland cancer	3.61e-06	2.84e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—salivary gland cancer	3.58e-06	2.82e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CREBBP—salivary gland cancer	3.57e-06	2.81e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CREBBP—salivary gland cancer	3.57e-06	2.81e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—EP300—salivary gland cancer	3.57e-06	2.81e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—EP300—salivary gland cancer	3.56e-06	2.8e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	3.52e-06	2.77e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	3.51e-06	2.76e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CCND1—salivary gland cancer	3.5e-06	2.75e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—PIK3CA—salivary gland cancer	3.49e-06	2.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—PIK3CA—salivary gland cancer	3.49e-06	2.75e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—EP300—salivary gland cancer	3.47e-06	2.74e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTEN—salivary gland cancer	3.46e-06	2.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTEN—salivary gland cancer	3.45e-06	2.71e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CCND1—salivary gland cancer	3.41e-06	2.68e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CREBBP—salivary gland cancer	3.39e-06	2.67e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CREBBP—salivary gland cancer	3.38e-06	2.66e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	3.38e-06	2.66e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PTEN—salivary gland cancer	3.38e-06	2.66e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—salivary gland cancer	3.37e-06	2.66e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PTEN—salivary gland cancer	3.36e-06	2.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—salivary gland cancer	3.36e-06	2.65e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOTCH1—salivary gland cancer	3.36e-06	2.65e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—CREBBP—salivary gland cancer	3.34e-06	2.63e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—CREBBP—salivary gland cancer	3.34e-06	2.63e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—EP300—salivary gland cancer	3.3e-06	2.6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PTEN—salivary gland cancer	3.29e-06	2.59e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—EP300—salivary gland cancer	3.29e-06	2.59e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	3.27e-06	2.57e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—salivary gland cancer	3.23e-06	2.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—salivary gland cancer	3.23e-06	2.54e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—EP300—salivary gland cancer	3.22e-06	2.53e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	3.21e-06	2.53e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—EP300—salivary gland cancer	3.21e-06	2.53e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOTCH1—salivary gland cancer	3.2e-06	2.52e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAP2K2—salivary gland cancer	3.15e-06	2.48e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NUP62—salivary gland cancer	3.15e-06	2.48e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—EP300—salivary gland cancer	3.14e-06	2.47e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—VCAN—salivary gland cancer	3.13e-06	2.46e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTEN—salivary gland cancer	3.11e-06	2.45e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—PIK3CA—salivary gland cancer	3.09e-06	2.43e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AQP1—salivary gland cancer	3.07e-06	2.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CREBBP—salivary gland cancer	3.05e-06	2.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PTEN—salivary gland cancer	3e-06	2.36e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOTCH1—salivary gland cancer	2.99e-06	2.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—EP300—salivary gland cancer	2.96e-06	2.33e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CCND1—salivary gland cancer	2.93e-06	2.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CREBBP—salivary gland cancer	2.9e-06	2.29e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CCND1—salivary gland cancer	2.9e-06	2.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—EP300—salivary gland cancer	2.86e-06	2.25e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—salivary gland cancer	2.86e-06	2.25e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CREBBP—salivary gland cancer	2.83e-06	2.23e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PTEN—salivary gland cancer	2.83e-06	2.23e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PIK3CA—salivary gland cancer	2.82e-06	2.22e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	2.82e-06	2.22e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CREBBP—salivary gland cancer	2.81e-06	2.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PTEN—salivary gland cancer	2.8e-06	2.21e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—PIK3CA—salivary gland cancer	2.78e-06	2.19e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—PIK3CA—salivary gland cancer	2.78e-06	2.19e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTEN—salivary gland cancer	2.77e-06	2.18e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	2.74e-06	2.16e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—PIK3CA—salivary gland cancer	2.73e-06	2.15e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CREBBP—salivary gland cancer	2.71e-06	2.14e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—EP300—salivary gland cancer	2.7e-06	2.12e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	2.69e-06	2.12e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—EP300—salivary gland cancer	2.67e-06	2.1e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CCND1—salivary gland cancer	2.64e-06	2.08e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CCND1—salivary gland cancer	2.64e-06	2.08e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—PIK3CA—salivary gland cancer	2.64e-06	2.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—EP300—salivary gland cancer	2.64e-06	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—PIK3CA—salivary gland cancer	2.63e-06	2.07e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—salivary gland cancer	2.61e-06	2.06e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOTCH1—salivary gland cancer	2.58e-06	2.04e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—salivary gland cancer	2.57e-06	2.03e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—salivary gland cancer	2.57e-06	2.03e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PIK3CA—salivary gland cancer	2.57e-06	2.02e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—salivary gland cancer	2.55e-06	2.01e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—salivary gland cancer	2.55e-06	2.01e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	2.52e-06	1.98e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CCND1—salivary gland cancer	2.51e-06	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CCND1—salivary gland cancer	2.5e-06	1.97e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PIK3CA—salivary gland cancer	2.48e-06	1.95e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—salivary gland cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PIK3CA—salivary gland cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—salivary gland cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NUP62—salivary gland cancer	2.43e-06	1.92e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—salivary gland cancer	2.43e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—salivary gland cancer	2.43e-06	1.92e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PIK3CA—salivary gland cancer	2.43e-06	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—salivary gland cancer	2.42e-06	1.91e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—salivary gland cancer	2.41e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—VCAN—salivary gland cancer	2.41e-06	1.9e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	2.4e-06	1.89e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—salivary gland cancer	2.38e-06	1.88e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—salivary gland cancer	2.38e-06	1.88e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PIK3CA—salivary gland cancer	2.38e-06	1.88e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—salivary gland cancer	2.38e-06	1.87e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PIK3CA—salivary gland cancer	2.37e-06	1.87e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CREBBP—salivary gland cancer	2.34e-06	1.85e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—salivary gland cancer	2.32e-06	1.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—salivary gland cancer	2.32e-06	1.82e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—salivary gland cancer	2.31e-06	1.82e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—salivary gland cancer	2.3e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—salivary gland cancer	2.3e-06	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	2.29e-06	1.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—salivary gland cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—salivary gland cancer	2.27e-06	1.79e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—salivary gland cancer	2.27e-06	1.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—salivary gland cancer	2.26e-06	1.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCND1—salivary gland cancer	2.25e-06	1.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—salivary gland cancer	2.25e-06	1.77e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—salivary gland cancer	2.24e-06	1.77e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—salivary gland cancer	2.2e-06	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—salivary gland cancer	2.2e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—salivary gland cancer	2.2e-06	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—salivary gland cancer	2.19e-06	1.73e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	2.19e-06	1.72e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—salivary gland cancer	2.18e-06	1.71e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCND1—salivary gland cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—salivary gland cancer	2.15e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—salivary gland cancer	2.14e-06	1.69e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—salivary gland cancer	2.12e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CREBBP—salivary gland cancer	2.08e-06	1.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—salivary gland cancer	2.07e-06	1.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—salivary gland cancer	2.07e-06	1.63e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CREBBP—salivary gland cancer	2.03e-06	1.6e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—salivary gland cancer	2.03e-06	1.6e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—salivary gland cancer	2.02e-06	1.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCND1—salivary gland cancer	2.01e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—salivary gland cancer	2e-06	1.58e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—salivary gland cancer	2e-06	1.57e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—salivary gland cancer	2e-06	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.99e-06	1.57e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—salivary gland cancer	1.98e-06	1.56e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—salivary gland cancer	1.98e-06	1.56e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	1.96e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—salivary gland cancer	1.96e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—salivary gland cancer	1.95e-06	1.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—salivary gland cancer	1.94e-06	1.53e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—salivary gland cancer	1.93e-06	1.52e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—salivary gland cancer	1.93e-06	1.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—salivary gland cancer	1.91e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—salivary gland cancer	1.91e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	1.87e-06	1.47e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—salivary gland cancer	1.85e-06	1.46e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—salivary gland cancer	1.85e-06	1.46e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—salivary gland cancer	1.85e-06	1.45e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—salivary gland cancer	1.83e-06	1.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—salivary gland cancer	1.81e-06	1.42e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—salivary gland cancer	1.8e-06	1.42e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—salivary gland cancer	1.8e-06	1.42e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.77e-06	1.4e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CREBBP—salivary gland cancer	1.76e-06	1.38e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—salivary gland cancer	1.74e-06	1.37e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—salivary gland cancer	1.74e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCND1—salivary gland cancer	1.73e-06	1.37e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—salivary gland cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—salivary gland cancer	1.7e-06	1.34e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—salivary gland cancer	1.68e-06	1.32e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—salivary gland cancer	1.68e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—salivary gland cancer	1.67e-06	1.32e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—salivary gland cancer	1.66e-06	1.31e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—salivary gland cancer	1.66e-06	1.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—salivary gland cancer	1.65e-06	1.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—salivary gland cancer	1.65e-06	1.3e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.62e-06	1.27e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—salivary gland cancer	1.6e-06	1.26e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—salivary gland cancer	1.58e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—salivary gland cancer	1.58e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CREBBP—salivary gland cancer	1.57e-06	1.24e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—salivary gland cancer	1.53e-06	1.21e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CREBBP—salivary gland cancer	1.53e-06	1.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—salivary gland cancer	1.48e-06	1.17e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—salivary gland cancer	1.48e-06	1.17e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—salivary gland cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—salivary gland cancer	1.45e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CREBBP—salivary gland cancer	1.44e-06	1.14e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CREBBP—salivary gland cancer	1.43e-06	1.13e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	1.43e-06	1.12e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—salivary gland cancer	1.42e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—salivary gland cancer	1.42e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—salivary gland cancer	1.41e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—salivary gland cancer	1.41e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.38e-06	1.09e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—salivary gland cancer	1.38e-06	1.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—salivary gland cancer	1.37e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—salivary gland cancer	1.35e-06	1.07e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—salivary gland cancer	1.32e-06	1.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—salivary gland cancer	1.27e-06	9.96e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—salivary gland cancer	1.26e-06	9.88e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CREBBP—salivary gland cancer	1.22e-06	9.62e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—salivary gland cancer	1.2e-06	9.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—salivary gland cancer	1.18e-06	9.3e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—salivary gland cancer	1.14e-06	8.99e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—salivary gland cancer	1.12e-06	8.82e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—salivary gland cancer	1.09e-06	8.61e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—salivary gland cancer	1.09e-06	8.6e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—salivary gland cancer	1.07e-06	8.41e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—salivary gland cancer	1.05e-06	8.23e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—salivary gland cancer	1.04e-06	8.21e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—salivary gland cancer	1.03e-06	8.11e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—salivary gland cancer	1.02e-06	8.05e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—salivary gland cancer	1.02e-06	8.04e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—salivary gland cancer	9.83e-07	7.74e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—salivary gland cancer	9.74e-07	7.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	9.43e-07	7.43e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—salivary gland cancer	8.85e-07	6.97e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—salivary gland cancer	8.73e-07	6.87e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—salivary gland cancer	8.32e-07	6.55e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—salivary gland cancer	7.9e-07	6.22e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	7.71e-07	6.07e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—salivary gland cancer	7.27e-07	5.72e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—salivary gland cancer	7.21e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—salivary gland cancer	6.74e-07	5.3e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—salivary gland cancer	6.42e-07	5.06e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—salivary gland cancer	6.16e-07	4.85e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	4.75e-07	3.74e-06	CbGpPWpGaD
